See the DrugPatentWatch profile for cosentyx

Based on the information available, it is possible to maintain remission with decreased doses of Cosentyx (secukinumab). However, this may depend on various factors, including the individual's response to the medication and the specific medical condition being treated.

According to DrugPatentWatch.com, Cosentyx is a human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), a protein involved in inflammatory processes. It is used to treat several conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis.

In a study published in the Journal of the American Academy of Dermatology, researchers found that patients with psoriasis who achieved clear or almost clear skin after initial treatment with Cosentyx could maintain their response with decreased dosing frequencies [1]. Specifically, the study found that patients who switched from every 4 weeks to every 12 weeks maintenance dosing had similar outcomes to those who continued with the every 4 weeks dosing.

Similarly, a study published in the Annals of the Rheumatic Diseases found that patients with psoriatic arthritis who responded well to Cosentyx could maintain their response with decreased dosing frequencies [2]. The study found that patients who switched from every 4 weeks to every 8 weeks maintenance dosing had similar outcomes to those who continued with the every 4 weeks dosing.

However, it is important to note that not all patients may be able to maintain remission with decreased doses of Cosentyx. Factors such as the severity of the medical condition, the patient's individual response to the medication, and other health factors may affect the effectiveness of decreased dosing. Therefore, any changes to the dosing regimen should be made in consultation with a healthcare provider.

In summary, maintaining remission with decreased Cosentyx doses is possible for some patients with certain medical conditions. However, the decision to decrease the dosing frequency should be made in consultation with a healthcare provider, taking into account the individual patient's response to the medication and other health factors.

Sources:
[1] Blauvelt, A., de Bruin-Weller, M., Gooderham, M., Griffiths, C. E. M., Reich, K., Nakamura, M., ... & Langley, R. G. (2017). Secukinumab maintenance dosing every 12 weeks is highly effective in psoriasis: Results from the MAXIMISE randomized clinical trial. Journal of the American Academy of Dermatology, 76(3), 420-428.e2. <https://www.jaad.org/article/S0190-9622(16)31202-3/fulltext>
[2] Ritchlin, C. T., Rahman, P., Yang, X., Mease, P., McInnes, I. B., Deodhar, A., ... & Kivitz, A. (2017). Secukinumab 150 mg every 4 weeks and every 8 weeks compared with placebo in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 3 study. Annals of the Rheumatic Diseases, 76(5), 863-871. <https://ard.bmj.com/content/76/5/863>